Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

Cesare Gridelli, Paul Baas, Fabrice Barlesi, Fortunato Ciardiello, Lucio Crinò, Enriqueta Felip, Shirish Gadgeel, Vali Papadimitrakopoulou, Luis Paz-Ares, David Planchard, Maurice Perol, Nasser Hanna, Assunta Sgambato, Francesca Casaluce, Filippo de Marinis

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Non–small-cell lung cancer (NSCLC) patients inevitably progress to first-line therapy and further active treatments are warranted. In the past few years, new second-line therapies, beyond chemotherapy agents, have become available in clinical practice. To date, several options for the second-line treatment of non–oncogene-addicted NSCLC patients ranging from chemotherapy in combination with antivascular endothelial growth factor receptor to immunotherapeutics are available. In oncogene-driven tumors, the better knowledge of mechanisms of acquired resistance to earlier tyrosine kinase inhibitors is leading to novel active inhibitors now available/in development. The second-line algorithm treatment of NSCLC becomes very intricate and the selection of proper patients with one of the new available therapeutic options is of paramount importance to personalize and optimize the treatment. In this review we discuss the second-line treatment opportunities of addicted as well as not-addicted NSCLC.

Original languageEnglish (US)
Pages (from-to)301-314
Number of pages14
JournalClinical Lung Cancer
Volume19
Issue number4
DOIs
StatePublished - Jul 2018

Keywords

  • Chemotherapy
  • Combination strategies
  • Immunotherapy
  • Second-line treatment
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology'. Together they form a unique fingerprint.

  • Cite this

    Gridelli, C., Baas, P., Barlesi, F., Ciardiello, F., Crinò, L., Felip, E., Gadgeel, S., Papadimitrakopoulou, V., Paz-Ares, L., Planchard, D., Perol, M., Hanna, N., Sgambato, A., Casaluce, F., & de Marinis, F. (2018). Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 19(4), 301-314. https://doi.org/10.1016/j.cllc.2017.12.010